Vivo Capital, LLC - Q2 2021 holdings

Add to watchlist

$2.31 Billion is the total value of Vivo Capital, LLC's 59 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 300.0% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
IMPL NewImpel NeuroPharma Inc$25,530,000–2,884,789
+100.0%
1.10%–
VALN NewValneva SEsponsored ads$10,540,000–400,000
+100.0%
0.46%–
MRUS BuyMerus NV$9,313,000
+154.7%
442,000
+152.6%
0.40%
+214.8%
ELEV NewElevation Oncology Inc$6,742,000–496,843
+100.0%
0.29%–
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ACLARIS THERAPEUTICS INC29Q3 202333.5%
CODEXIS INC29Q3 20238.0%
ASCENDIS PHARMA A/S25Q3 202224.0%
KALVISTA PHARMACEUTICALS INC25Q3 20233.9%
Verona Pharma PLC ADR24Q3 20237.6%
AMYRIS INC23Q3 20238.8%
EIGER BIOPHARMACEUTICALS INC23Q1 20228.7%
Zai Lab Ltd ADR22Q3 20231.8%
Arrowhead Pharmaceuticals Inc21Q3 20236.9%
HOMOLOGY MEDICINES INC21Q3 20233.7%

View Vivo Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Vivo Capital, LLC Q2 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
SINOVAC BIOTECH LTDSold outAugust 27, 201800.0%

View Vivo Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-04-22
13F-HR2024-02-07
13F-HR2023-11-08
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-13
13F-HR2022-02-11

View Vivo Capital, LLC's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (2310073000.0 != 2310071000.0)

Export Vivo Capital, LLC's holdings

CSVXLS